FindTrial
Sign In

Pen auto-injector

DEVICE13 trials

Sponsors

Sanofi

Conditions

Diabetes Mellitus Type 2Diabetes Mellitus, Type 2Type 2 Diabetes Mellitus

Phase 2

Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
CompletedNCT01175473
SanofiType 2 Diabetes Mellitus
Start: 2010-08-31End: 2010-11-30Updated: 2016-11-28

Phase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy
CompletedNCT00688701
SanofiDiabetes Mellitus, Type 2
Start: 2008-05-31End: 2009-12-31Updated: 2016-12-12
GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
CompletedNCT00707031
SanofiDiabetes Mellitus, Type 2
Start: 2008-06-30End: 2010-11-30Updated: 2016-12-02
GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
CompletedNCT00712673
SanofiDiabetes Mellitus, Type 2
Start: 2008-06-30End: 2011-03-31Updated: 2016-12-15
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
CompletedNCT00713830
SanofiDiabetes Mellitus, Type 2
Start: 2008-07-31End: 2011-01-31Updated: 2016-12-14
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
CompletedNCT00715624
SanofiDiabetes Mellitus, Type 2
Start: 2008-07-31End: 2011-02-28Updated: 2016-11-28
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
CompletedNCT00763815
SanofiDiabetes Mellitus Type 2
Start: 2008-09-30End: 2011-06-30Updated: 2016-11-28
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
CompletedNCT00763451
SanofiDiabetes Mellitus, Type 2
Start: 2008-09-30End: 2011-01-31Updated: 2016-12-14
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
CompletedNCT00866658
SanofiDiabetes Mellitus, Type 2
Start: 2009-03-31End: 2010-06-30Updated: 2016-10-11
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
CompletedNCT00905255
SanofiDiabetes Mellitus, Type 2
Start: 2009-05-31End: 2011-01-31Updated: 2016-12-21
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
CompletedNCT00975286
SanofiType 2 Diabetes Mellitus
Start: 2009-10-31End: 2011-08-31Updated: 2016-10-11
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
CompletedNCT00976937
SanofiType 2 Diabetes Mellitus
Start: 2009-08-31End: 2011-03-31Updated: 2016-10-11
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
CompletedNCT01169779
SanofiType 2 Diabetes Mellitus
Start: 2010-07-31End: 2011-12-31Updated: 2016-10-13

Related Papers

Impact of Type 2 Diabetes Duration on the Efficacy and Safety of Add-on Lixisenatide in Asian Individuals Receiving Basal Insulin: A Pooled Analysis.
2023-02-21
Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data
Clinical Diabetes and Endocrinology2020-01-143 citations
Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.
2016-06-184 citations
Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.
2016-06-015 citations
Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study
Hormone and Metabolic Research2015-06-0313 citations
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
2013-02-25148 citations